1de Faria GP, de 01iveira JA, de Oliveira JG, et al. Differences in the expression pattern of P-glycoprotein and MRP1 in low-grade and high- grade gliomas. Cancer Invest,200$ ,26:883-889.
6Liu X, Howard KA, Dong M, et al. The influence of polymeric proper- ties on chitosarr/siRNA nanoparticle formulation and gene silencing. Biomaterials ,2007,28 : 1280 -1288.
7Koping - Hogggtrd M, Tubulekas I, Guan H,et al. Chitosan as a non- viral gene delivery system. Structure-property relationships and charac- teristics compared with polyethylenimine in vitro and after lung admin- istration in vivo. Gene Ther,2001,8:1108-1121.
3Yang LY, Trujillo JM . Biological characterization of multi- drug resistant human colon carcinoma sublines induced/ selected by two methods[J]. Cancer Res, 1990, 50(6): 3218- 3225.
4Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, ceL- lular, and pharmacological aspects of the multidrug trans- porter [J]. Annu Rev Pharmacol Toxicol, 1999, 39(8): 361- 398.
5Krishna R, Mayer LD. Multidrug resistance (MDR) in can- cer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs [J]. Eur J Pharm Sci, 2000, 11(4): 265- 283.
6Ling V. Muhidrug resistance: molecular mechanisms and clinical relevance. [J]. Cancer Chemother Pharmcol, 1997, 40 (Suppl): S3-8.
7Loe DW, Deeley RG, Cole SPC. Biology of the multidrug resistance associated protein MRP [J]. Eur J Cancer, 1996, 32A(6): 945-957.
8Daschner PJ, Ciolino HP, Plouzek CK, et al. Increased AP-I activity in drug resistant human breast cancer MCF-7 cells [J]. Breast Cancer Res Treat, 1999, 53(3): 229-240.
9Cole SP, Bhardwaj G, Gerlach JH, et al. Over-expression of a transporter gene in a muhidrug-resistant human lung cancer cell line [J]. Science, 1992, 258(5088): 1650-1654.
10Ishikawa T, Li ZS, Lu YP. The GS-X pump in plant, yeast, and animal ceils: structure, function, and gene expression [J]. Biosci Rep, 1997, 17(2): 159-207.